Close Menu

NEW YORK – Metabolon announced on Wednesday that it had closed on $72 million in combined debt and equity financing.

In a statement, company President and CEO Rohan Hastie said that it planned to use the funding to grow its client base and further its R&D programs using machine learning for biomarker discovery and precision medicine.

The round included new investor Perceptive Advisors as well as existing investors including EW Healthcare Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.